MalawiTuberculosis profile
Population  2016 18 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.9 (1.4–4.8) 16 (8–27)
Mortality (HIV+TB only) 6 (3.2–9.7) 33 (18–54)
Incidence  (includes HIV+TB) 29 (15–46) 159 (85–256)
Incidence (HIV+TB only) 15 (9.9–22) 85 (55–121)
Incidence (MDR/RR-TB)** 0.4 (0.13–0.67) 2.2 (0.72–3.7)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1 (0.47–1.6) 11 (5.1–17) 12 (5.5–18)
Males 1.2 (0.54–1.8) 16 (7.2–24) 17 (7.8–26)
Total 2.2 (1–3.4) 27 (12–41) 29 (15–46)
TB case notifications, 2016  
Total cases notified 16 959
Total new and relapse 15 516
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 96%
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 54% (34–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.33 (0.14–0.56)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 8 592 53%
          - on antiretroviral therapy 8 334 97%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  210
(110–310)
Estimated % of TB cases with MDR/RR-TB 0.75% (0–1.6) 6.4% (3.8–8.9)  
% notified tested for rifampicin resistance     2 897
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 66, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 59, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 81% 15 597
Previously treated cases, excluding relapse, registered in 2015 76% 1 284
HIV-positive TB cases registered in 2015 81% 7 799
MDR/RR-TB cases started on second-line treatment in 2014 58% 53
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 50%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
50% (46–55)
TB financing, 2017  
National TB budget (US$ millions) 31
Funding source: 7% domestic, 76% international, 17% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data